Pozen tries again to win approval for Trexima

Pozen said it will initiate a toxicity trial of its migraine treatment Trexima on human subjects in an attempt to ease FDA concerns and obtain regulatory approval for the drug. The biotech firm also has sent additional safety data to the FDA in response to an approvable letter the agency issued for Trexima.

View Full Article in:

News & Observer (Raleigh, N.C.), The · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA